Inhibikase Therapeutics

Clinical-stage cardiopulmonary pharma

IKT · Nasdaq · United States

Share price · IKT

$1.38-1.02 (-42.50%) 3M

close as of 2026-11-18 · 24h delayed · vol 425K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IKT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026-7.7%
  2. 9 Nov 2026+12.0%

    Nothing announced by IKT that day or the session before.

  3. 3 Nov 2026-3.9%
  4. 30 Oct 2026-7.2%

    Nothing announced by IKT that day or the session before.

  5. 26 Oct 2026-4.4%

    Nothing announced by IKT that day or the session before.

  6. 16 Oct 2026-9.8%
  7. 4 Aug 2026+10.4%

    Nothing announced by IKT that day or the session before.

  8. 23 Jul 2026+7.4%
  9. 20 Jul 2026+5.7%

    Nothing announced by IKT that day or the session before.

  10. 18 Jun 2026+8.9%

    Nothing announced by IKT that day or the session before.

Share of unusual movement by asset

For each asset, the share of IKT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—25%
Sessions with no dated event—75%

No dated announcements about its assets since 2 Jul 2024.

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PDGFR (imatinib-class)Small molecule
Pulmonary Arterial Hypertension
Phase 2
c-AblSmall molecule
Parkinson's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
Imatinib mesylate prodrug (IkT-001Pro)Phase 3Pulmonary Arterial Hypertension
Est. primary completion 2029-06 · NCT07365332 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Imatinib mesylate prodrug (IkT-001Pro)Phase 3Pulmonary Arterial Hypertension (PAH)
Est. primary completion 2030-06-30 · NCT07632898 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$15M$52M+ $142M short-term inv.$20M-$17M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$13M$31M+ $128M short-term inv.$20M-$12M operating cash flowreport ↗
2026-Q1$0$11M$50M+ $121M short-term inv.$16M-$12M operating cash flowreport ↗
2025-Q3$0$7.7M$38M+ $39M short-term inv.$12M-$11M operating cash flowreport ↗
2025-Q2$0$5.3M$78M+ $9.9M short-term inv.$9.9M-$5.6M operating cash flowreport ↗
2025-Q1$0$11M$73M+ $20M short-term inv.$14M-$4.1M operating cash flowreport ↗
2024-Q3$0$4.2M$0.9M+ $2.3M short-term inv.$5.8M-$4.9M operating cash flowreport ↗
2024-Q2$0$3.1M$3.1M+ $4.8M short-term inv.$5.0M-$5.0M operating cash flowreport ↗
2024-Q1$0$2.8M$2.4M+ $7.4M short-term inv.$4.7M-$3.9M operating cash flowreport ↗
2023-Q3$0.1M$3.2M$15M+ $2.0M short-term inv.$4.6M-$4.1M operating cash flowreport ↗
2023-Q2$0.1M$4.5M$1.9M+ $19M short-term inv.$5.8M-$4.6M operating cash flowreport ↗
2023-Q1$0.1M$2.9M$4.0M+ $22M short-term inv.$4.5M-$6.0M operating cash flowreport ↗
2022-Q3<$0.1M$3.0M$5.8M+ $21M short-term inv.$4.5M-$5.5M operating cash flowreport ↗
2022-Q2<$0.1M$3.0M$32M$4.6M-$4.4M operating cash flowreport ↗
2022-Q1$0.1M$3.0M$37M$4.6M-$3.9M operating cash flowreport ↗
2021-Q3$0.3M$3.1M$45M$4.5M-$2.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$30M$139M+ $40M short-term inv.$12M-$28M operating cash flowreport ↗

Inhibikase Therapeutics reported no disclosed revenue for 2025 (prior year $0M), with R&D spend of $29.79M, up 73.1% YoY. Cash and equivalents were $139.22M, while total cash, cash equivalents and marketable securities were $178.8M as of December 31, 2025. The company reported a net loss of $48.26M, or $0.49 per share, for the year.

The company is advancing IKT-001 into the global pivotal Phase 3 IMPROVE-PAH study in pulmonary arterial hypertension, with regulatory submissions filed in over 20 countries, first U.S. sites activated, and acceptance under the EU FAST-EU pilot initiative. The two-part adaptive study includes Part A in approximately 140 patients with a primary endpoint of pulmonary vascular resistance at Week 24, and Part B in approximately 346 patients with a primary endpoint of six-minute walk distance at Week 24, expected to run at up to about 180 sites worldwide. Inhibikase also completed a $115 million underwritten public offering in November 2025 and completed pre-clinical studies supporting a potential FDA Orphan Drug Designation application for IKT-001.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$17M$56M+ $41M short-term inv.$6.9M-$19M operating cash flowreport ↗
2023-FY$0.3M$14M$9.2M+ $4.1M short-term inv.$4.8M-$18M operating cash flowreport ↗
2022-FY$0.1M$12M$7.2M+ $16M short-term inv.$4.5M-$17M operating cash flowreport ↗
2021-FY$3.1M$11M$41M+ $0 short-term inv.$3.7M-$14M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($3.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-19Wasserman Scott M. · directorAward / grant (derivative)310,000——Form 4
2026-07-30BERMAN DENNIS N · directorOption exercise21,854$1.26$28KForm 4
2026-07-30BERMAN DENNIS N · directorOption exercise (derivative)21,854——Form 4
2026-07-29RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOther (see filing)18,030,000——Form 4
2026-07-29RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% ownerOther (see filing) (derivative)18,030,000——Form 4
2026-06-26Munshi Amit · directorAward / grant (derivative)155,000——Form 4
2026-06-26Aurentz Vincent · directorAward / grant (derivative)155,000——Form 4
2026-06-26Bellini Roberto · directorAward / grant (derivative)155,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 104 reporting institutions held 117.8M shares ($197.5M, 84.0% of shares outstanding).

#InstitutionSharesValue
1Sands Capital Alternatives, LLC13,018,965$21.9M
2Soleus Capital Management, L.P.10,875,000$18.3M
3Fairmount Funds Management LLC8,625,000$14.5M
4Trails Edge Capital Partners, LP8,057,345$13.5M
5ADAR1 Capital Management, LLC6,606,572$11.1M
6Kalehua Capital Management LLC6,494,498$10.9M
7BlackRock, Inc.6,303,433$10.6M
8Blackstone Inc.5,938,276$10.0M
9Siren, L.L.C.5,850,000$9.8M
10Commodore Capital LP5,397,488$9.1M
11VANGUARD CAPITAL MANAGEMENT LLC4,450,665$7.5M
12Saturn V Capital Management LP3,863,445$6.5M
13Spruce Street Capital LP3,581,603$6.0M
14Squadron Capital Management LLC3,500,000$5.9M
15MILLENNIUM MANAGEMENT LLC2,928,077$4.9M